Investment
Features
FeesSafety
Academy
More
Pluang+

Instacart CEO to speak at Goldman Sachs tech conference on Sept 9, 2026

Market News
26 Aug 2026
PRNewsWire
View Source
Neutral
pluang ai news

Instacart announced that CEO Chris Rogers will participate in a fireside chat at the Goldman Sachs Communacopia & Technology Conference on September 9, 2026. The event will be webcast live on Instacart's Investor Relations website. This appearance provides insight into Instacart's future plans and performance, important for investors tracking the grocery technology company's growth and strategy.

More News

BP shifts assets and invests in Brazil amid mixed analyst ratings.

BP shifts assets and invests in Brazil amid mixed analyst ratings.

BP, a major global energy company, is actively managing its portfolio by potentially selling oil and gas assets in Egypt to Energean and investing in new projects like a Halliburton contract in Brazil's offshore field. This strategic move aims to enh...

Market News
Neutral
13 minutes ago
Pernod Ricard beats Q4 2026 earnings estimates despite sales declines in US and China.

Pernod Ricard beats Q4 2026 earnings estimates despite sales declines in US and China.

Pernod Ricard reported Q4 2026 earnings per share of $0.42 and revenue of $4.90 billion, both surpassing analyst expectations. However, the company faces significant organic sales declines of 14% in the US and 19% in China due to weak consumer demand...

Company Fundamentals
Neutral
1 hour ago
Diodes Inc. stock up 19% in 30 days despite recent 12% dip, with strong analyst target of $192.

Diodes Inc. stock up 19% in 30 days despite recent 12% dip, with strong analyst target of $192.

Diodes Incorporated's stock surged 19.27% over the past 30 days, showing strong market momentum despite a recent 12.30% pullback in the last 10 days. This decline has brought the stock to a local low, potentially attracting investors looking for entr...

Analyst Insights
Bullish
1 hour ago
Alterity Therapeutics advances neurological drugs with stable $8.67 price target, some optimism at $12.

Alterity Therapeutics advances neurological drugs with stable $8.67 price target, some optimism at $12.

Alterity Therapeutics Limited is developing experimental drugs ATH434 and PBT2 targeting Parkinson's and Alzheimer's diseases. The consensus analyst price target remains steady at $8.67, reflecting consistent market confidence, while some analysts li...

Analyst Insights
Neutral
1 hour ago
Canadian Solar Q2 results mixed; revenue beats but losses widen, price target cut to $15

Canadian Solar Q2 results mixed; revenue beats but losses widen, price target cut to $15

Canadian Solar reported mixed Q2 2026 results with a GAAP net loss of $1.40 per share, wider than expected, but revenue of $1.21 billion exceeded estimates. Battery-storage shipments grew 73% year-over-year, while solar-module shipments fell 60% year...

Company Fundamentals
Bearish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App